Chemistry:Baxdrostat
Baxdrostat is an investigational drug that is being evaluated for the treatment of hypertension.[1] It is an aldosterone synthase inhibitor.[2][3]
Mechanism of action
Aldosterone dysregulation contributes significantly to the pathogenesis of resistant hypertension.[4] While conventional drugs act by blocking the mineralocorticoid receptor, baxdrostat, an aldosterone synthase inhibitor, targets the aldosterone synthesis directly. [2]
Clinical trials
BrigHTN
In adults with treatment-resistant hypertension, treatment with baxdrostat at doses of 1 mg or 2 mg daily produced significantly greater reductions in systolic blood pressure over 12 weeks compared to placebo.[5]
BaxHTN
BaxHTN is a phase 3 trial.[6] It found that adding once-daily baxdrostat to standard antihypertensive therapy led to significantly greater reductions in seated systolic blood pressure at 12 weeks compared with placebo, in adults with uncontrolled or resistant hypertension. [7][6]
References
- ↑ "Baxdrostat - CinCor Pharma". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800054826.
- ↑ 2.0 2.1 "Baxdrostat: A Novel Aldosterone Synthase Inhibitor for Treatment Resistant Hypertension". Current Problems in Cardiology 48 (11). November 2023. doi:10.1016/j.cpcardiol.2023.101918. PMID 37399857.
- ↑ "Evaluating phase II results of Baxdrostat, an aldosterone synthase inhibitor for hypertension". Expert Opinion on Investigational Drugs 32 (11): 985–995. October 2023. doi:10.1080/13543784.2023.2276755. PMID 37883217.
- ↑ "Aldosteronism and resistant hypertension". International Journal of Hypertension 2011. January 2011. doi:10.4061/2011/837817. PMID 21331160.
- ↑ "Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension". The New England Journal of Medicine 388 (5): 395–405. February 2023. doi:10.1056/NEJMoa2213169. PMID 36342143.
- ↑ 6.0 6.1 "Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension". The New England Journal of Medicine 393 (14): 1363–1374. October 2025. doi:10.1056/NEJMoa2507109. PMID 40888730.
- ↑ "Baxdrostat demonstrated statistically significant and clinically meaningful reduction in systolic blood pressure in patients with hard-to-control hypertension in the BaxHTN Phase III trial" (in az). 2025-08-30. https://www.astrazeneca.com/content/az-us/media/press-releases/2025/Baxdrostat-demonstrated-statistically-significant-and-clinically-meaningful-reduction-in-systolic-blood-pressure-in-patients-with-hard-to-control-hypertension-in-the-BaxHTN-Phase-III-trial.html.
 |  |
